Skip to main content
OpenTrials
Completed

NCT Number: NCT03207776

An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD

Patients who are hospitalized at select Carolinas Healthcare System (CHS) sites with Chronic Obstructive Pulmonary Disorder (COPD) acute exacerbation symptoms will be treated per the CHS COPD Clinical Pathway. Patient outcomes will be followed, including but not limited to readmission. Patients on the pathway will also have access to navigator services.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Carolinas Healthcare System - Pineville, Charlotte, North Carolina, United States

Loading trial locations.

About this study

Patients hospitalized at participating CHS sites with COPD acute exacerbation symptoms, will be treated per the CHS COPD clinical pathway. The COPD clinical pathway will include four components: (i) discrete, evidence-based care steps (ii) patient navigation, (iii) daily data driven care gap identification, (iv) monthly leadership huddles. These components are all part of usual care for patients in this population, but each component is not applied to patients consistently across the System. For this reason, the pathway will be applied consistently and completely in patients meeting COPD acute exacerbation criteria at participating sites. Patients will be followed for 60 days in total after discharge from their COPD acute exacerbation symptoms to determine the potential effectiveness of complete implementation of all 4 components in the care of COPD patients. Patients on the pathway will also have access to navigator services.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Identified as having an acute exacerbation of COPD within 24 hours of admission

Exclusion criteria

  • Death during the index encounter
  • No initial discharge as of the end of the study period

Treatment and study plan

Usual Care

Other

Treatment of patients in the usual manner based on their diagnosis and resources available at that site.

COPD Clinical Pathway

Other

A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services.

Primary outcomes

  1. Healthcare Utilization

    Time frame: 60 days

    Occurrence of Emergency Department, inpatient, or observation encounters after the initial encounter at accrual

Secondary outcomes

  1. Quality, Comfort, and Care (QCC) Defined Readmission Rate

    Time frame: 30 days

    Readmission to the same facility

  2. Patient-centric (Protocol Defined) Readmission Rate

    Time frame: 30 days

    Readmission to any facility within Carolinas HealthCare System

  3. 30-day COPD Specific, Acute Care Utilization to Any Hospital Within the System

    Time frame: 30 day

Sponsors and collaborators

Lead sponsor

Wake Forest University Health Sciences

Other

Registry information

Official study title

A Cluster Randomized, Stepped-Wedge Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of Chronic Obstructive Pulmonary Disorder (COPD)

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jul 5, 2017
Registry last updated
Apr 22, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.